These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
672 related articles for article (PubMed ID: 26588173)
1. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan. Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173 [TBL] [Abstract][Full Text] [Related]
2. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Avigdor A; Bulvik S; Levi I; Dann EJ; Shemtov N; Perez-Avraham G; Shimoni A; Nagler A; Ben-Bassat I; Polliack A Ann Oncol; 2010 Jan; 21(1):126-32. PubMed ID: 19608615 [TBL] [Abstract][Full Text] [Related]
3. Early chemotherapy de-escalation strategy in patients with advanced-stage Hodgkin lymphoma with negative positron emission tomography scan after 2 escalated BEACOPP cycles. Długosz-Danecka M; Szmit S; Kocurek A; Koźlik P; Giza A; Zimowska-Curyło D; Małkowski B; Sowa-Staszczak A; Kużdżał J; Jurczak W Pol Arch Intern Med; 2019 Apr; 129(4):259-266. PubMed ID: 30945698 [TBL] [Abstract][Full Text] [Related]
4. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ; N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708 [TBL] [Abstract][Full Text] [Related]
5. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients. Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704 [TBL] [Abstract][Full Text] [Related]
6. Early intensification treatment approach in advanced-stage Hodgkin lymphoma. Borchmann P Hematol Oncol Clin North Am; 2014 Feb; 28(1):65-74. PubMed ID: 24287068 [TBL] [Abstract][Full Text] [Related]
7. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592 [TBL] [Abstract][Full Text] [Related]
8. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma. Ganesan P; Rajendranath R; Kannan K; Radhakrishnan V; Ganesan TS; Udupa K; Lakshmipathy KM; Mahajan V; Sundersingh S; Rajaraman S; Krishnakumar R; Sagar TG Ann Oncol; 2015 Jun; 26(6):1170-1174. PubMed ID: 25701453 [TBL] [Abstract][Full Text] [Related]
10. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages? Diehl V; Fuchs M; Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996 [TBL] [Abstract][Full Text] [Related]
11. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483 [TBL] [Abstract][Full Text] [Related]
12. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. André MPE; Carde P; Viviani S; Bellei M; Fortpied C; Hutchings M; Gianni AM; Brice P; Casasnovas O; Gobbi PG; Zinzani PL; Dupuis J; Iannitto E; Rambaldi A; Brière J; Clément-Filliatre L; Heczko M; Valagussa P; Douxfils J; Depaus J; Federico M; Mounier N Cancer Med; 2020 Sep; 9(18):6565-6575. PubMed ID: 32710498 [TBL] [Abstract][Full Text] [Related]
13. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Wannesson L; Bargetzi M; Cairoli A; Cerutti A; Heim D; Hess U; Lerch E; Pabst T; Renner C; Samaras P; Zucca E Leuk Lymphoma; 2013 Jan; 54(1):36-40. PubMed ID: 22702653 [TBL] [Abstract][Full Text] [Related]
14. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Mounier N; Brice P; Bologna S; Briere J; Gaillard I; Heczko M; Gabarre J; Casasnovas O; Jaubert J; Colin P; Delmer A; Devidas A; Bachy E; Nicolas-Virelizier E; Aoudjhane A; Humbrecht C; Andre M; Carde P; Ann Oncol; 2014 Aug; 25(8):1622-8. PubMed ID: 24827123 [TBL] [Abstract][Full Text] [Related]
15. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. Borchmann P; Haverkamp H; Diehl V; Cerny T; Markova J; Ho AD; Eich HT; Mueller-Hermelink HK; Kanz L; Greil R; Rank A; Paulus U; Smardova L; Huber C; Dörken B; Nerl C; Krause SW; Mueller RP; Fuchs M; Engert A J Clin Oncol; 2011 Nov; 29(32):4234-42. PubMed ID: 21990399 [TBL] [Abstract][Full Text] [Related]
16. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence. Seshachalam A; Karpurmath SV; Rathnam K; Raman SG; Janarthinakani M; Prasad K; Patil C; Anoop P; Reddy N; Anumula SK; Roopa SP; Golamari KR; Danthala M; Gunari P; Malipatil B; Rangarajan B; Udupa KS; Nandennavar M; Niraimathi K; Shewade HD J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31834832 [TBL] [Abstract][Full Text] [Related]
17. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis]. Tarasenkova AA; Filatova LV; Gershanovich ML; Semiglazova TIu Vopr Onkol; 2012; 58(1):101-9. PubMed ID: 22629838 [TBL] [Abstract][Full Text] [Related]
18. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of standard BEACOPP regimen versus ABVD regimen for treatment of advanced Hodgkin's lymphoma. Lin N; He C; Zhang Q; Hong X; Liu L; Yang S; Su H; Li X; Dai X; Li Y; Zhu J J Cancer Res Ther; 2024 Aug; 20(4):1258-1264. PubMed ID: 39206988 [TBL] [Abstract][Full Text] [Related]
20. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma]. Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]